Met Life Investment Management, LLC Recursion Pharmaceuticals, Inc. Transaction History
Met Life Investment Management, LLC
- $18.1 Billion
- Q1 2025
A detailed history of Met Life Investment Management, LLC transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Met Life Investment Management, LLC holds 148,007 shares of RXRX stock, worth $618,669. This represents 0.0% of its overall portfolio holdings.
Number of Shares
148,007
Previous 149,808
1.2%
Holding current value
$618,669
Previous $1.01 Million
22.73%
% of portfolio
0.0%
Previous 0.01%
Shares
26 transactions
Others Institutions Holding RXRX
# of Institutions
365Shares Held
286MCall Options Held
3.28MPut Options Held
3.16M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl34.8MShares$146 Million1.99% of portfolio
-
Vanguard Group Inc Valley Forge, PA32.3MShares$135 Million0.0% of portfolio
-
Baillie Gifford & CO24.4MShares$102 Million0.12% of portfolio
-
Black Rock Inc. New York, NY17.3MShares$72.4 Million0.0% of portfolio
-
Softbank Group Corp Minato Ku Tokyo, M014.7MShares$61.3 Million0.27% of portfolio
About RECURSION PHARMACEUTICALS, INC.
- Ticker RXRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 180,480,000
- Market Cap $754M
- Description
- Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...